MXPA04003597A - Conjugados polimericos de antagonistas opiaceos. - Google Patents

Conjugados polimericos de antagonistas opiaceos.

Info

Publication number
MXPA04003597A
MXPA04003597A MXPA04003597A MXPA04003597A MXPA04003597A MX PA04003597 A MXPA04003597 A MX PA04003597A MX PA04003597 A MXPA04003597 A MX PA04003597A MX PA04003597 A MXPA04003597 A MX PA04003597A MX PA04003597 A MXPA04003597 A MX PA04003597A
Authority
MX
Mexico
Prior art keywords
polymer conjugates
polymer
opioid
opioid antagonists
conjugates
Prior art date
Application number
MXPA04003597A
Other languages
English (en)
Inventor
Cheng Lin
Original Assignee
Nektar Therapeutics Al Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics Al Corp filed Critical Nektar Therapeutics Al Corp
Publication of MXPA04003597A publication Critical patent/MXPA04003597A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invencion proporciona conjugados polimericos de antagonistas opiaceos que comprenden un polimetro, tal como por ejemplo, poli(etilenglicol), unido covalentemente a un antagonista opiaceo. El enlace entre el polimero y antagonista opiaceo de preferencia es hidroliticamente estable. La invencion tambien incluye un metodo para tratar uno o mas efectos secundarios asociados con el uso de analgesicos, opiaceos, tales como por ejemplo, constipacion, nauseas o prurito, al administrar uno de los conjugados polimericos de la invencion.
MXPA04003597A 2001-10-18 2002-10-18 Conjugados polimericos de antagonistas opiaceos. MXPA04003597A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33040001P 2001-10-18 2001-10-18
PCT/US2002/033325 WO2003032990A2 (en) 2001-10-18 2002-10-18 Polymer conjugates of opioid antagonists

Publications (1)

Publication Number Publication Date
MXPA04003597A true MXPA04003597A (es) 2004-07-30

Family

ID=23289594

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003597A MXPA04003597A (es) 2001-10-18 2002-10-18 Conjugados polimericos de antagonistas opiaceos.

Country Status (15)

Country Link
US (4) US7056500B2 (es)
EP (3) EP2939696B1 (es)
JP (2) JP4814488B2 (es)
KR (2) KR101009309B1 (es)
AU (1) AU2002360284B2 (es)
CA (1) CA2463938C (es)
CY (1) CY1119906T1 (es)
DK (2) DK1436012T3 (es)
ES (2) ES2569262T3 (es)
HK (1) HK1215171A1 (es)
LT (1) LT1436012T (es)
MX (1) MXPA04003597A (es)
PT (2) PT1436012T (es)
SI (2) SI2939696T1 (es)
WO (1) WO2003032990A2 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
CA2385533C (en) * 1999-10-04 2008-03-25 Shearwater Corporation Polymer stabilized neuropeptides
MXPA04003597A (es) 2001-10-18 2004-07-30 Nektar Therapeutics Al Corp Conjugados polimericos de antagonistas opiaceos.
CA2473526C (en) 2002-01-18 2013-10-22 Biogen Idec Ma Inc. Polyalkylene polymer compounds and uses thereof
WO2004091622A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
CA2521420A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US7482376B2 (en) * 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
US8637650B2 (en) 2003-11-05 2014-01-28 Genovoxx Gmbh Macromolecular nucleotide compounds and methods for using the same
AU2014280956B2 (en) * 2003-12-16 2016-09-22 Nektar Therapeutics Chemically modified small molecules
PL1694363T3 (pl) * 2003-12-16 2014-07-31 Nektar Therapeutics Monodyspersyjne kompozycje PEGylowanego naloksolu
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
MXPA06010764A (es) * 2004-03-23 2006-12-15 Amgen Inc Metodos y composiciones de proteinas quimicamente modificadas.
JP2008501797A (ja) * 2004-06-08 2008-01-24 マリンクロッド・インコーポレイテッド アヘンからのアルカロイド類の抽出
WO2006064780A1 (ja) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. 便秘治療剤
MX2007008756A (es) * 2005-01-20 2007-09-27 Progenics Pharm Inc Uso de metilnaltrexona y compuestos relacionados para el tratamiento de disfuncion gastrointestinal postoperatoria.
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
AU2007240680B2 (en) 2006-04-21 2013-05-02 Nektar Therapeutics Stereoselective reduction of a morphinone
EP2402037B8 (en) 2006-05-26 2019-12-04 Signature Therapeutics, Inc. Controlled release of phenolic opioids
MX2009004965A (es) * 2006-11-07 2009-06-05 Nektar Therapeutics Al Corp Formas de dosificacion y co-administracion de un agonista de opioides y un antagonista de opioides.
WO2008064353A2 (en) * 2006-11-22 2008-05-29 Progenics Pharmaceuticals, Inc. 7,8-saturated-4,5-epoxy-morphinanium analogs
US20110105381A2 (en) * 2007-02-16 2011-05-05 Pharmacofore, Inc. Prodrugs of Peripheral Phenolic Opioid Antagonists
US20140011964A1 (en) 2007-02-28 2014-01-09 Serina Therapeutics, Inc. Activated Polyoxazolines and Conjugates and Compositions Comprising the Same
KR101508617B1 (ko) * 2007-02-28 2015-04-06 세리나 쎄라퓨틱스, 인코포레이티드 활성화된 폴리옥사졸린 및 이를 포함하는 조성물
CA2679479C (en) * 2007-03-12 2015-10-06 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
EP2134718A2 (en) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
US8883817B2 (en) * 2007-10-18 2014-11-11 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2723685C (en) * 2008-05-07 2016-09-27 Nektar Therapeutics Oral administration of peripherally-acting opioid antagonists
ES2620373T3 (es) 2008-07-01 2017-06-28 University Of Chicago Partículas que contienen un antagonista del receptor de opioides periférico
JP5588983B2 (ja) 2008-08-11 2014-09-10 ウェルズ ファーゴ バンク ナショナル アソシエイション マルチアームポリマーアルカノエートコンジュゲート
CA2734333A1 (en) * 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CA2774021A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
WO2011050938A1 (de) 2009-10-26 2011-05-05 Genovoxx Gmbh Konjugate von nukleotiden und methoden zu deren anwendung
PE20130063A1 (es) 2010-03-11 2013-02-11 Wyeth Llc Formulaciones orales y sales lipofilicas de metilnaltrexona
PL2621496T5 (pl) 2010-09-30 2019-05-31 Astrazeneca Ab Krystaliczny koniugat naloksol-peg
WO2012083197A1 (en) 2010-12-17 2012-06-21 Nektar Therapeutics Water-soluble polymer conjugates of topotecan
WO2012088282A1 (en) 2010-12-21 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
KR102016305B1 (ko) * 2011-11-07 2019-08-30 넥타르 테라퓨틱스 오피오이드 작용제 화합물 및 진통제 화합물의 조성물, 투여형 및 공동 투여
US9795689B2 (en) * 2012-09-11 2017-10-24 University Of Massachusetts Crosslinked polymer nano-assemblies and uses thereof
JP6384964B2 (ja) 2012-10-30 2018-09-05 ネクター セラピューティクス オピオイド作動薬としてのα−６−ＭＰＥＧ６−Ｏ−ヒドロキシコドンの固体塩およびその使用
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
ME02946B (me) * 2014-04-28 2018-04-20 Orphomed Inc Dimer buprenorfina i njegova upotreba u lecenju gastrointestinalnih poremecaja
JP6371463B2 (ja) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 即時放出性乱用抑止性液体充填剤形
US10314839B2 (en) 2014-10-20 2019-06-11 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10017519B2 (en) 2015-04-27 2018-07-10 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof
US10226456B2 (en) 2015-04-27 2019-03-12 3St Research Llc Methods and compositions for preventing opioid abuse
US10449190B2 (en) 2015-04-27 2019-10-22 John K. Thottathil Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
WO2017041095A1 (en) 2015-09-03 2017-03-09 Allegheny-Singer Research Institute Hydrophilic fentanyl derivatives
CN107033154B (zh) * 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
US11590241B2 (en) 2016-02-18 2023-02-28 Virginia Commonwealth University Nanoparticle conjugated synthetic opioid prodrugs and methods of their uses
CN108210933B (zh) * 2016-12-22 2021-05-04 北京键凯科技股份有限公司 一种地佐辛与聚乙二醇的结合物
MX2020000638A (es) * 2017-07-20 2020-07-29 Suzhou Runxindatai Pharmaceutics Ltd Co Profármacos opioides de acción prolongada resistentes al abuso.
EP3826635A4 (en) 2018-07-23 2022-04-27 Trevi Therapeutics, Inc. TREATMENT OF CHRONIC COUGH, DIFFICULT BREATHING AND DYSPNEA
WO2020205537A1 (en) * 2019-03-29 2020-10-08 Allegheny Singer Research Institute Covalent modification and controlled delivery of mu opioid receptor antagonists
WO2024134619A1 (en) 2022-12-23 2024-06-27 Sintalica S.R.L. Non-hallucinogenic tryptamine compounds, preparation, pharmaceutical compositions and uses thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2433883C2 (de) * 1973-07-20 1986-03-27 Research Corp., New York, N.Y. Verwendung von physiologisch aktiven Polypeptiden
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4864781A (en) * 1981-06-17 1989-09-12 Emblin Robert T Multiple panel metal roofing system with overlapping panel edges
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
FR2514644A1 (fr) 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4730048A (en) 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4806556A (en) 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
DK0386644T3 (da) 1989-03-10 1997-10-13 Hoffmann La Roche Reagenser til bestemmelse af lægemidler
JPH0383914A (ja) 1989-08-18 1991-04-09 W R Grace & Co ドラッグキャリアー
US5130126A (en) 1990-07-09 1992-07-14 Nippon Oil & Fats Co., Ltd. Polymer-drug conjugate and a method of producing it
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
US5270328A (en) 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5250542A (en) 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
AU4406793A (en) 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5569450A (en) 1993-03-17 1996-10-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5434171A (en) 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
DE69709646T2 (de) 1996-03-12 2002-08-14 Alza Corp., Palo Alto Zusammensetzung und dosisform mit einem opioid-antagonisten
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
RS50070B (sr) * 1997-12-22 2009-01-22 Euro-Celtique S.A., Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
DK1061954T3 (da) 1998-03-12 2004-10-18 Nektar Therapeutics Al Corp Polyethylenglycolderivater med proximale reaktive grupper
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
EP0995757A3 (en) 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
CA2394980C (en) * 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
EP2517710B1 (en) * 2000-02-08 2015-03-25 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
ATE326222T1 (de) 2000-03-15 2006-06-15 Wolfgang Sadee Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
US7829074B2 (en) * 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
EP1355671A2 (en) * 2000-11-30 2003-10-29 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of triazine derivatives
CA2437989A1 (en) 2001-02-20 2002-08-29 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6756354B2 (en) * 2001-09-05 2004-06-29 Deanna Jean Nelson Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates
US20030054030A1 (en) * 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
MXPA04003597A (es) 2001-10-18 2004-07-30 Nektar Therapeutics Al Corp Conjugados polimericos de antagonistas opiaceos.
WO2003037384A2 (en) 2001-10-29 2003-05-08 Nektar Therapeutics Al, Corporation Polymer conjugates of protein kinase c inhibitors
WO2003037385A1 (en) 2001-10-30 2003-05-08 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of retinoic acid
CA2497195C (en) 2001-12-14 2014-07-08 The University Of Wyoming Methods and compositions for controlled release of drugs
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
EP1603597B1 (en) 2003-03-13 2010-01-06 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
PL1694363T3 (pl) * 2003-12-16 2014-07-31 Nektar Therapeutics Monodyspersyjne kompozycje PEGylowanego naloksolu
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
AU2007240680B2 (en) * 2006-04-21 2013-05-02 Nektar Therapeutics Stereoselective reduction of a morphinone
MX2009004965A (es) 2006-11-07 2009-06-05 Nektar Therapeutics Al Corp Formas de dosificacion y co-administracion de un agonista de opioides y un antagonista de opioides.
WO2009032246A2 (en) * 2007-09-03 2009-03-12 Nanotherapeutics, Inc. Particulate compositions for delivery of poorly soluble drugs
KR102612902B1 (ko) 2016-04-22 2023-12-18 삼성디스플레이 주식회사 투명 전도막 및 이를 포함하는 전자 소자

Also Published As

Publication number Publication date
EP1436012A2 (en) 2004-07-14
DK1436012T3 (en) 2018-01-22
EP2939696A1 (en) 2015-11-04
KR20050037423A (ko) 2005-04-21
EP2939696B1 (en) 2016-03-09
CA2463938A1 (en) 2003-04-24
US7662365B2 (en) 2010-02-16
CY1119906T1 (el) 2018-06-27
US8349307B2 (en) 2013-01-08
US20100105715A1 (en) 2010-04-29
LT1436012T (lt) 2018-04-10
ES2654819T3 (es) 2018-02-15
KR100974842B1 (ko) 2010-08-11
US20030124086A1 (en) 2003-07-03
SI1436012T1 (en) 2018-03-30
DK2939696T3 (en) 2016-05-23
CA2463938C (en) 2011-08-09
JP2005506351A (ja) 2005-03-03
KR20090130155A (ko) 2009-12-17
WO2003032990A3 (en) 2004-02-26
JP4814488B2 (ja) 2011-11-16
AU2002360284C1 (en) 2003-04-28
JP2009167214A (ja) 2009-07-30
PT2939696E (pt) 2016-06-17
ES2569262T3 (es) 2016-05-09
WO2003032990A2 (en) 2003-04-24
SI2939696T1 (sl) 2016-06-30
JP5570137B2 (ja) 2014-08-13
PT1436012T (pt) 2018-03-27
US20130165466A1 (en) 2013-06-27
HK1215171A1 (zh) 2016-08-19
US7056500B2 (en) 2006-06-06
EP2236161A1 (en) 2010-10-06
US8617530B2 (en) 2013-12-31
EP1436012B1 (en) 2017-12-20
AU2002360284B2 (en) 2006-11-02
KR101009309B1 (ko) 2011-01-18
US20060105046A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
MXPA04003597A (es) Conjugados polimericos de antagonistas opiaceos.
WO2003037384A3 (en) Polymer conjugates of protein kinase c inhibitors
WO2001037785A3 (en) Novel methods and compositions involving opioids and antagonists thereof
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
PT914097E (pt) Composicao e forma de dosagem compreendendo antagonista de opioide
MY137535A (en) New pyrrolidinium derivatives
NZ331001A (en) Use of an opiate K receptor agonist as an antipruritic
DE60038290D1 (de) Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen
WO2001082899A3 (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
EP1363629A4 (en) KAPPA OPIOID RECEPTOR LIGANDS
AU7522601A (en) Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
HK1064614A1 (en) Use of methylnaltrexone to treat immune suppression
WO2000071518A3 (en) Heterocyclic analgesic compounds and their use
CA2334460A1 (en) Pharmaceutical compositions comprising alpha-adrenoceptor antagonists and muscarinic antagonists
AU6518998A (en) Morphinane derivatives and medicinal use thereof
BR0207978A (pt) N-but-3enil norbuprenorfina e métodos de uso
AU2003250391A1 (en) Conjugates of biocompatible polymers with nuclide activation therapy reagents
WO2001068604A3 (en) 3-substituted piperidines comprising urea functionality, and methods of use thereof
UA82983C2 (ru) Полимерные коньюгаты найбластина и способы их использования
EP1262196A3 (en) Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
WO2005065712A3 (en) Complexes having adjuvant activity
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
WO2002043713A3 (de) Verwendung von schwachen opioiden und gemischten opioidagonisten / -antagonisten zur therapie der harninkontinenz
IL148856A0 (en) Novel fluoroalkylsubstituted cyclotrisiloxanes, their use for preparation of new polymers and novel polymers
CY1117608T1 (el) Πολυμερικες συζευξεις οπιοειδων ανταγωνιστων

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights